Familial cancer · 2013
The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Teo Zhi L, Sawyer Sarah D, James Paul A, Mitchell Gillian, Trainer Alison H, Lindeman Geoffrey J, Shackleton Kylie, Cicciarelli Linda, Southey Melissa C
Аннотация
The familial aggregation of breast cancer has been well-described with approximately 25% of breast cancers attributable to inherited mutations in currently known breast cancer susceptibility genes. PALB2 c.3113G>A (p.Trp1038*) is a protein-truncating mutation which has been associated with high estimated risk of breast cancer in Australian women (91%; 95% CI = 44-100) to age 70 years. This study screened for PALB2 c.3113G>A in germline DNA representing 871 unrelated individuals from "high-risk" breast and/or ovarian cancer families evaluated in the setting of a Familial Cancer Centre in Australia. The PALB2 c.3113G>A mutation was identified in eight of 871 probands (0.92%) from these families. Median age of diagnosis was 42 years. Five of these eight women had contra-lateral breast cancers. Available data suggests that PALB2 c.3113G>A is a rare mutation with estimated breast cancer risks similar in magnitude to that associated with BRCA2 mutations. Although the proportion of high-risk women carrying this PALB2 mutation is low, research efforts should continue in order to effect its translation into clinical genetic testing practice.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAustraliaBreast NeoplasmsCancer Care FacilitiesDNA, NeoplasmFanconi Anemia Complementation Group N ProteinFemaleGenetic Predisposition to DiseaseGenetic TestingHumansIncidenceMiddle AgedMutationNuclear ProteinsOvarian NeoplasmsPolymerase Chain ReactionPrognosisTumor Suppressor ProteinsYoung Adult